Structural analysis of the amyloidogenic κ Bence Jones protein (FUR)

Amyloid

Volumn 6, Issue 2, 1999, Pages 77-88

  Odani, Shoji ^a   Komori, Yukako ^a   Gejyo, Fumitake ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

AL amyloidosis; Amino acid sequence of Bence Jones protein; Bence Jones protein of kappa type; Mass spectrometry of amyloid fibril proteins; Multiple myeloma

Indexed keywords

AMYLOID; BENCE JONES PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; PROTEINASE;

AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOIDOSIS; ANOREXIA; ARTICLE; AUTOPSY; CASE REPORT; FATIGUE; HUMAN; MACROGLOSSIA; MALE; MASS SPECTROMETRY; MOLECULAR MODEL; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

EID: 0032779934     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129909007307     Document Type: Article

References (37)

1. 1 Kelly JW (1996). Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opinion in Struct Biol 6, 11-17
2. 2 Glenner GG, Harbaugh J, Ohma JI, Harada M and Cuatrecasas P (1970). An amyloid protein, the amino-terminal variable fragment of immunoglobulin light chain. Biochem Biophys Res Commun 41, 1287-1289
3. 3 Glenner GG, Terry W, Harada M, Isersky D and Page D (1971). Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 172, 1150-1151
4. 4 Benson MD, Kluve-Beckerman B, Liepnieks JJ, Murrell JR, Hanes D, and Uemichi T (1996). Metabolism of amyloid proteins. Ciba Found Symp 199,104-113
5. 5 Hurle MR, Helms LR, Lin L, Chan W and Wetzel R (1994). A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 91, 5446-5450
6. 6 Schormann N, Murrell JR, Liepnieks JJ and Benson MD (1995). Tertiary structure of an amyloid immunoglobulin light chain protein: A proposed model for amyloid fibril formation. Proc Natl Acad Sci USA 92, 9490-9494
7. 7 Glenner GG, Harada M and Isersky C (1972). The purification of amyloid fibril proteins. Prep Biochem 2, 39-51
8. 8 Laemmli UK (1970). Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227, 680-685
9. 9 Schagger H and von Jagow G (1987). Tricine-sodium dodecylsulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166, 368-379
10. 10 Matsubara, H and Sasaki, RM (1969). High recovery of tryptophan from acid hydrolysates of proteins. Biochem Biophys Res Commun 35, 175-181
11. 11 LeGendre N, Mansfield M, Weiss A and Matsudaira P (1993). Purification of proteins and peptides by SDS-PAGE. In Matsudaira P (ed.) A practical guide to protein and peptide purification for microsequencing, pp. 74-101. San Diego: Academic Press
12. 12 Pearson WR (1990). Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol 183, 63-98
13. 13 Yamamoto A, Toda H and Sakiyama F (1989). Vapor-phase hydrazinolysis for microdetermination of carboxyl-terminal amino acids of proteins. J Biochem (Tokyo) 106, 552-554
14. 14 Peitsch MC (1996). ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem Soc Trans 24, 274-279
15. 15 Guex N. and Peitsch MC (1997). SWISS-MODEL and the Swiss-PdbViewer. An environment for comparative protein modeling. Electrophoresis 18, 2714-2723
16. 16 Eigenbrot C, Randal M, Presta L, Carter P and Kossiakoff, AA (1993). X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 229, 969-995
17. 17 Casale E, Wenisch E, He XM, Righetti PG, Snyder RS, Jungbauer A, Tauer C, Ruker F and Carter DC (1990). Crystallization of the Fab from a human monoclonal antibody against gp 41 of human immunodeficiency virus type I. J Mol Biol 216, 511-512
18. 18 Eigenbrot C, Gonzalez T, Mayeda J, Carter P, Werther W, Hotaling T, Fox J and Kessler J (1994). X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65. Proteins 18, 49-62
19. 19 Banfield MJ, King DJ, Mountain A amd Brady RL (1997). VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs. Proteins 29, 161-171
20. 20 Wedemayer GJ, Wang LH, Patten PA, Schultz PG and Stevens RC (1997). Crystal structures of the free and liganded form of an esterolytic catalytic antibody. J Mol Biol 268, 390-400
21. 21 Jeffrey PD, Bajorath J, Chang CY, Yelton D, Hellstrom I, Hellstrom KE and Sheriff S (1995). The x-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol 2, 466-471
22. 22 Guex N (1996). Swiss-PdbViewer: A new fast and easy to use PDB viewer for the Macintosh. Experimentia 52, A26
23. 23 Narita K, Matsuo H and Nakajima T (1975). End group determination. In Needlemann SB (ed.) Protein sequence determination, pp. 30-103, Berlin: Springer-Verlag
24. 24 Kyle RA and Bayrd ED (1975). Amyloidosis: review of 236 cases. Medicine (Baltimore) 54, 271-299
25. 25 Johnson G, Kabat EA and Wu TT (1996). Kabat database of sequences of proteins of immunological interest. In Herzenberg LA and Weir WM (eds.) Weir's handbook of experimental immunology I. Immunochemistry and molecular immunology, pp. 1-21. Cambridge, MA: Blackwell Science
26. 26 Kelly JW, Colon W, Lai Z, Lashuel, HA, McCulloch J, McCutchen SL, Miroy GJ and Peterson SA (1997). Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 50, 161-181
27. 27 Colon W and Kelly JW (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8655-8660
28. 28 Stevens PW, Raffen R, Hanson DK, Deng Y-L, Berrios-Hammond M, Westholm FA, Murphy C, Eulitz M, Wetzel R, Solomon A, Schiffer M, and Stevens FJ (1995). Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci 4, 421-432
29. 29 Dwulet FE, Strako K and Benson MD (1985). Amino acid sequence of a λVI primary (AL) amyloid protein (WLT). Scand J Immunol 22, 653-660
30. 30 Stevens FJ, Myatt EA, Chang C-H, Westholm FA, Eulitz M, Weiss DT, Murphy C, Solomon A, and Schiffer M (1995). A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry 34, 10697-10702
31. 31 Bellotti V, Merlinin G, Bucciarelli E, Perfetti V, Quaglini S, and Ascari E (1990). Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Brit J Haematol 74, 65-69
32. 32 Gallo G, Goñi F, Boctor F, Vidal R, Kumar A, Stevens FJ, Frangione B, and Ghiso J (1996). Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits. Am J Pathol 148, 1397-1406
33. 33 Klfaki H-W, Kratzin HD, Pick AI, Eckart K, Karas M, and Hilschmann N (1992). Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis. Biochemistry 31, 3265-3272
34. 34 Resnick NM, Maloy WL, Guy HR and Zasloff M (1991). A novel endopeptidase from Xenopus that recognizes α-helical secondary structure. Cell 66, 541-554
35. 35 Yamada T, Liepnieks JJ, Kluve-Beckerman B and Benson MD (1995). Cathepsin B generates the most common from of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 41, 94-97
36. 36 Nelson SR, Lyon M, Gallagher JT, Johnson EA, and Pepys MB (1991). Isolation and characterization of the integral glycosamino-glycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J 275, 67-73
37. 37 Chan W, Helms LR, Brooks I, Lee G, Ngola S, McNulty D, Maleeff B, Hensley P and Wetzel R (1996). Mutational effects on inclusion body formation in the periplasmic expression of the immunoglobulin VL domain RE1. Fold Des 1, 77-89